Our Team
At Nouvogenes Therapeutics, our leadership team brings together deep expertise in gene editing science, clinical strategy, and biotech entrepreneurship. United by a shared vision—to transform the treatment of chronic genetic diseases through curative CRISPR-based therapies—we are building a company grounded in scientific rigor, clinical impact, and responsible innovation.
Veerachat Petpisit, MD Chief Executive Officer
A physician by training and life sciences leader by experience, Dr. Petpisit brings over 15 years of leadership across global pharmaceutical and biotech companies, spanning clinical development, commercialization, and corporate strategy. With a deep commitment to improving lives through innovation, he leads Nouvogenes Therapeutics’ mission to deliver durable gene therapies for high-burden diseases such as Transfusion-Dependent Thalassemia. His vision blends scientific precision with a strong understanding of global health needs, ensuring the company remains patient-focused and globally minded.
Chairat Uthaipibull, PhD
Chief Scientific Officer
Dr. Uthaipibull brings world-class expertise in molecular biology, CRISPR gene editing, and translational research. With a distinguished career spanning academic research, R&D leadership and innovation management, he oversees Nouvogenes Therapeutics’ scientific strategy and preclinical development efforts. His focus is on advancing proprietary gene editing platforms, optimizing therapeutic design, and ensuring a rigorous path from discovery to clinical proof-of-concept.
